Pennsylvania is currently home to 3310 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Philadelphia, Pittsburgh, Hershey and Allentown. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Dichoptic Treatment for Amblyopia in Children 4 to 7 Years of Age
NCT06380517
Recruiting
In children 4 to 7 years of age, to determine if treatment with 1 hour per day 6 days per week of watching dichoptic movies/shows wearing the Luminopia headset is non-inferior to treatment with 2 hours of patching per day 7 days per week with respect to change in amblyopic eye distance VA from randomization to 26 weeks.
Gender:
ALL
Ages:
Between 4 years and 7 years
Trial Updated:
06/09/2025
Locations: Pediatric Ophthalmology of Erie, Erie, Pennsylvania
Conditions: Amblyopia
Register for Updates
Rapid Outpatient Low-dose Initiation of Buprenorphine for OUD With Fentanyl Use
NCT06379984
Recruiting
The goal of this clinical trial is to learn if buprenorphine can be started for opioid use disorder with fentanyl use without requiring or precipitating opioid withdrawal. To be eligible, participants must have moderate or severe opioid use disorder and must have fentanyl detected on a urine drug test. Participants will be admitted to a monitored research unit for the trial. They will be randomized to start buprenorphine with either standard initiation or with a new approach called rapid outpat... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/09/2025
Locations: University of Pennsylvania Center for Studies of Addiction, Philadelphia, Pennsylvania
Conditions: Opioid Use Disorder
Register for Updates
Reverse-Engineering of Exclusive Enteral Nutrition (RE-EEN) in Crohn's Disease: A Multi-Center Trial
NCT06216899
Recruiting
This study will compare the tolerability and efficacy of conventional formula Exclusive Enteral Nutrition (EEN) and whole-food blended smoothie EEN by enrolling a total of 60 participants with newly diagnosed pediatric Crohn's disease (CD). Participants will be provided either commercial formula or guided on the preparation of the home-blended smoothie. These participants will be given a specific recipe, blender, and be provided the food components to the smoothie. The study will total 8 weeks... Read More
Gender:
ALL
Ages:
Between 8 years and 21 years
Trial Updated:
06/09/2025
Locations: Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
Conditions: Crohn Disease
Register for Updates
MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)
NCT06128629
Recruiting
To evaluate the efficacy and safety of a single dose of NTLA-2001 compared to placebo in participants with ATTR-CM.
Gender:
ALL
Ages:
Between 18 years and 90 years
Trial Updated:
06/09/2025
Locations: Penn Presbyterian Medical Center, Philadelphia, Pennsylvania
Conditions: Transthyretin Amyloidosis (ATTR) With Cardiomyopathy
Register for Updates
CTSN Embolic Protection Trial
NCT06027788
Recruiting
This is a prospective, multi-center, randomized effectiveness trial of the CardioGard Embolic Protection Cannula in high-risk valve surgery patients.
Gender:
ALL
Ages:
60 years and above
Trial Updated:
06/09/2025
Locations: Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania
Conditions: Delirium, Ischemic Stroke, Acute Kidney Injury, Heart Valve Disease, Coronary Artery Disease
Register for Updates
A Study to Evaluate the Efficacy and Safety of CIN-102 (Deudomperidone) in Adults With Diabetic Gastroparesis
NCT05832151
Recruiting
The goal of this clinical trial is to evaluate if the study drug CIN-102 (deudomperidone) can help reduce the symptoms associated with diabetic gastroparesis in adult patients. The main questions it aims to answer are: * To evaluate the efficacy of CIN-102 on symptoms of gastroparesis when given to patients with diabetic gastroparesis compared to a placebo * To evaluate the safety and tolerability of CIN-102 when given to patients with diabetic gastroparesis compared to a placebo Participants... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/09/2025
Locations: Susquehanna Research Group, LLC, Harrisburg, Pennsylvania
Conditions: Diabetic Gastroparesis
Register for Updates
Janus Kinase (JAK) Inhibitors to Preserve C-Peptide Production in New Onset Type 1 Diabetes (T1D)
NCT05743244
Recruiting
A multi-center, placebo-controlled, double blind, 1:1:1 randomized control clinical trial testing two different JAK Inhibitors abrocitnib, ritlecitinib, and placebo in subjects with recent onset Stage 3 Type 1 Diabetes within 100 days of diagnosis.
Gender:
ALL
Ages:
Between 12 years and 35 years
Trial Updated:
06/09/2025
Locations: University of Pittsburgh, Pittsburgh, Pennsylvania
Conditions: Diabetes Mellitus, Type 1
Register for Updates
Safety and Tolerability Subretinal OPGx-001 for LCA5-Associated Inherited Retinal Degeneration (LCA5-IRD)
NCT05616793
Recruiting
The goal of this clinical trial is to evaluate the safety and preliminary efficacy of subretinal gene therapy with OPGx-001 in patients with inherited retinal degeneration due to biallelic mutations in the LCA5 gene. Funding Source- FDA Office of Orphan Products Development (OOPD).
Gender:
ALL
Ages:
13 years and above
Trial Updated:
06/09/2025
Locations: University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania
Conditions: LCA5
Register for Updates
Safety and Efficacy of PC945 (Opelconazole) in Combination With Other Antifungal Therapy for the Treatment of Refractory Invasive Pulmonary Aspergillosis (OPERA-T Study)
NCT05238116
Recruiting
To assess the safety and efficacy of nebulized PC945 in combination with systemic antifungal therapy for the treatment of refractory IPA
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/09/2025
Locations: Clinical Research Site 002, Philadelphia, Pennsylvania
Conditions: Refractory IPA
Register for Updates
Percutaneous or Surgical Repair In Mitral Prolapse And Regurgitation for ≥60 Year-olds (PRIMARY)
NCT05051033
Recruiting
This is a prospective, multicenter, open-label, randomized trial comparing mitral valve (MV) transcatheter edge-to-edge repair (TEER) to surgical repair (1:1 ratio) in patients with primary, degenerative mitral regurgitation (MR). The trial will be conducted in the U.S., Canada, Germany and the United Kingdom, and is designed as a strategy trial. Thus, all devices legally marketed for TEER of primary degenerative MR in a particular country are eligible to be used in this trial.
Gender:
ALL
Ages:
65 years and above
Trial Updated:
06/09/2025
Locations: Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania
Conditions: Mitral Valve Regurgitation
Register for Updates
Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer
NCT04787744
Recruiting
This is a prospective, open-label, multi-center seamless phase II to phase III randomized clinical trial designed to compare SST with or without PET-directed local therapy in improving the castration-resistant prostate cancer-free survival (CRPC-free survival) for Veterans with oligometastatic prostate cancer. Oligometastasis will be defined as 1-10 sites of metastatic disease based on the clinical determination of the LSI which incorporates all imaging, clinical, and pathologic data available.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
06/09/2025
Locations: Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA, Philadelphia, Pennsylvania
Conditions: Prostate Cancer, Oligometastasis, Oligorecurrence, Recurrent Prostate Cancer, Metastatic Prostate Cancer, De Novo Prostate Cancer
Register for Updates
RA-PRO PRAGMATIC TRIAL
NCT04692493
Recruiting
The 2021 ACR RA treatment guideline, based on widely acknowledged low to moderate quality evidence, recommends switching to a non-tumor necrosis factor (TNFi) biologic (choose among existing medications, currently, rituximab, abatacept, tocilizumab, or sarilumab) or a targeted synthetic DMARD arm (tsDMARD; choose among existing medications, currently, tofacitinib, baricitinib, upadacitinib) in patients with active RA despite the use of a TNFi-biologic. In practice, most patients receive another... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/09/2025
Locations: Altoona Center for Clinical Research, Duncansville, Pennsylvania
Conditions: Rheumatoid Arthritis
Register for Updates